TNF and synovitis: Diffuse or myeloid synovitis affects 50–70% of patients, is associated with good responses to anti-TNF drugs, and has one of the most benign clinical phenotypes, where rheumatoid factors tend to be absent, CD68+ cells predominate, and there are few lymphocytes and no ectopic lymphoid structures (39–41).